Advertisement

Hormones

pp 1–12 | Cite as

Pediatric growth hormone therapy in Greece: analysis of the Hellenic cohort of the GeNeSIS study

  • I. Kosteria
  • K. AloumanisEmail author
  • C. Kanaka-Gantenbein
  • E. Vlachopapadopoulou
  • S. Michalacos
  • L. Stamoyannou
  • E. Drossinos
  • G. Chrousos
  • for the Hellenic GeNeSIS study group
Original Article
  • 8 Downloads

Abstract

Purpose

To describe the data from the Greek cohort of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).

Methods

GeNeSIS was a prospective, open-label, multinational, observational study collecting information on clinical outcomes and treatment safety of children with growth disorders treated with growth hormone (GH), according to national indications. After informed consent, 305 patients (143 females), including 255 patients with growth hormone deficiency (GHD) and 30 with Turner syndrome (TS), from eight investigational sites, were enrolled in Greece. Demographic data, treatment efficacy, and adverse events were reported at the discretion of attending physicians.

Results

Treatment with GH was undertaken for 247/255 patients with GHD and 29/30 with TS. The majority of patients treated with GHD (73.7%) and TS (84%) with recorded Tanner stage were prepubertal at enrolment. Among patients treated with GHD and TS, 70.45% and 55% were GH-naïve at study entry, respectively. Height standard deviation score (SDS), height velocity SDS, and height SDS-target height SDS numerically improved during the 4-year observation period. The effect of GH treatment was more prominent in the first year of treatment, especially in the GHD group.

Conclusions

In the Greek cohort of GeNeSIS, GHD is the most frequent indication for GH treatment, followed by TS. While the latter is diagnosed somewhat earlier, GH treatment is not as efficacious as for patients with GHD. No major safety issues were reported during follow-up. The results, which are in accordance with the international literature, should be interpreted in the context of observational studies.

Keywords

Growth hormone Turner syndrome Children Growth hormone treatment Height velocity 

Notes

Acknowledgments

The authors would like to thank Christopher Jeremy Child, Research Advisor, for the help in the preparation of the manuscript.

Compliance with ethical standards

Conflict of interest

A.K and D.E. are employed by Pharmaserve Lilly SACI. The GeNeSIS study was sponsored by Eli-Lilly.

References

  1. 1.
    Kirk J (2012) Indications for growth hormone therapy in children. Arch Dis Child 97:63–68.  https://doi.org/10.1136/adc.2010.186205 CrossRefPubMedGoogle Scholar
  2. 2.
    Grimberg A, DiVall SA, Polychronakos C et al (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 19104:361–397.  https://doi.org/10.1159/000452150 CrossRefGoogle Scholar
  3. 3.
    Gravholt CH, Andersen NH, Conway GS et al (2017) Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177:G1–G70.  https://doi.org/10.1530/EJE-17-0430 CrossRefPubMedGoogle Scholar
  4. 4.
    Bell J, Parker KL, Swinford RD et al (2010) Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167–177.  https://doi.org/10.1210/jc.2009-0178 CrossRefPubMedGoogle Scholar
  5. 5.
    Darendeliler F, Karagiannis G, Wilton P (2007) Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res Paediatr 68:41–47.  https://doi.org/10.1159/000110474 CrossRefGoogle Scholar
  6. 6.
    Clayton PE, Cowell CT (2000) Safety issues in children and adolescents during growth hormone therapy--a review. Growth Hormon IGF Res 10:306–317.  https://doi.org/10.1054/ghir.2000.0175 CrossRefGoogle Scholar
  7. 7.
    Raman S, Grimberg A, Waguespack SG et al (2015) Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab 100:2192–2203.  https://doi.org/10.1210/jc.2015-1002 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ranke MB, Lindberg A, Tanaka T et al (2017) Baseline characteristics and gender differences in prepubertal children treated with growth hormone in Europe, USA, and Japan: 25 years’ KIGS® experience (1987-2012) and review. Horm Res Paediatr 87:30–41.  https://doi.org/10.1159/000452887 CrossRefPubMedGoogle Scholar
  9. 9.
    Kaplowitz PB, Shulman DI, Frane JW et al (2013) Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS). Int J Pediatr Endocrinol 2013:9.  https://doi.org/10.1186/1687-9856-2013-9 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Polak M, Konrad D, Tønnes Pedersen B et al (2018) Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet® International Outcome Study. J Pediatr Endocrinol Metab 31:521–532.  https://doi.org/10.1515/jpem-2017-0489 CrossRefPubMedGoogle Scholar
  11. 11.
    Swerdlow AJ, Cooke R, Albertsson-Wikland K et al (2015) Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 84:172–183.  https://doi.org/10.1159/000435856 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schoenfeld A, Redberg R (2016) The value of using registries to evaluate randomized clinical trial study populations. JAMA 316:1153–1154.  https://doi.org/10.1001/jama.2016.8708 CrossRefGoogle Scholar
  13. 13.
    Humatrope 6mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC) - (eMC). https://www.medicines.org.uk/emc/product/3780/smpc. Accessed 14 Jul 2019
  14. 14.
    GH Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990–3993.  https://doi.org/10.1210/jcem.85.11.6984 CrossRefGoogle Scholar
  15. 15.
    Ogden CL, Kuczmarski RJ, Flegal KM et al (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60CrossRefGoogle Scholar
  16. 16.
    Preece MA (1994) Evaluation of growth and development. In: Holliday M, Barratt T, Avner E, Kogan B (eds) Pediatric nephrology, 3rd edn. Williams & Wilkins, Baltimore, pp 378–396Google Scholar
  17. 17.
    Cappa M, Iughetti L, Loche S et al (2016) Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. J Endocrinol Investig 39:667–677.  https://doi.org/10.1007/s40618-015-0418-0 CrossRefGoogle Scholar
  18. 18.
    Tai S, Tanaka T, Hasegawa T et al (2013) An observational study of the effectiveness and safety of growth hormone (Humatrope(®)) treatment in Japanese children with growth hormone deficiency or Turner syndrome. Endocr J 60:57–64PubMedGoogle Scholar
  19. 19.
    Luzuriaga Tomás C, Oyarzabal Irigoyen M, Caveda Cepas E et al (2016) Safety and efficacy of growth hormone treatment: GeNeSIS study in Spain. An Pediatr (Barc) 84:139–147.  https://doi.org/10.1016/j.anpedi.2015.05.002 CrossRefGoogle Scholar
  20. 20.
    Deal C, Hasselmann C, Pfäffle RW et al (2013) Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm Res Paediatr 79:283–292.  https://doi.org/10.1159/000350829 CrossRefPubMedGoogle Scholar
  21. 21.
    Pfäffle R (2015) Hormone replacement therapy in children: the use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab 29:339–352.  https://doi.org/10.1016/j.beem.2015.04.009 CrossRefPubMedGoogle Scholar
  22. 22.
    Deal C, Kirsch S, Chanoine J-P et al (2018) Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study. C Open 6:372–383.  https://doi.org/10.9778/cmajo.20180020 CrossRefGoogle Scholar
  23. 23.
    Wit JM, Massarano AA, Kamp GA et al (1992) Growth hormone secretion in patients with Turner’s syndrome as determined by time series analysis. Acta Endocrinol 127:7–12CrossRefGoogle Scholar
  24. 24.
    Ranke MB, Lindberg A, Chatelain P et al (1999) Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 84:1174–1183.  https://doi.org/10.1210/jcem.84.4.5634 CrossRefPubMedGoogle Scholar
  25. 25.
    Pfäffle R, Land C, Schönau E et al (2018) Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS). Horm Res Paediatr 90:169–180.  https://doi.org/10.1159/000492397 CrossRefPubMedGoogle Scholar
  26. 26.
    Hochberg Z, Zadik Z (1999) Final height in young women with Turner syndrome after GH therapy: an open controlled study. Eur J Endocrinol 141:218–224CrossRefGoogle Scholar
  27. 27.
    Sas TC, de Muinck Keizer-Schrama SM, Stijnen T et al (1999) Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84:4607–4612.  https://doi.org/10.1210/jcem.84.12.6241 CrossRefPubMedGoogle Scholar
  28. 28.
    van Pareren YK, Duivenvoorden HJ, Slijper FMEE et al (2005) Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Turner syndrome. Horm Res 63:238–244.  https://doi.org/10.1159/000085841 CrossRefPubMedGoogle Scholar
  29. 29.
    Quigley CA, Crowe BJ, Anglin DG, Chipman JJ (2002) Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 87:2033–2041.  https://doi.org/10.1210/jcem.87.5.8477 CrossRefPubMedGoogle Scholar
  30. 30.
    Léger J, Olivieri A, Donaldson M et al (2014) European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr 81:80–103.  https://doi.org/10.1159/000358198 CrossRefPubMedGoogle Scholar
  31. 31.
    Polak M, Blair JC, Kotnik P, et al (2017) Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet(®) International Outcome Study. Eur J Endocrinol EJE-16-1024.  https://doi.org/10.1530/EJE-16-1024
  32. 32.
    Ranke MB, Lindberg A, Chatelain P et al (2000) Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. J Clin Endocrinol Metab 85:4212–4218.  https://doi.org/10.1210/jcem.85.11.6976 CrossRefPubMedGoogle Scholar
  33. 33.
    Hughes IP, Choong CS, Harris M et al (2011) Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol 74:473–480.  https://doi.org/10.1111/j.1365-2265.2011.03937.x CrossRefGoogle Scholar
  34. 34.
    Land C, Blum WF, Shavrikova E et al (2007) Predicting the growth response to growth hormone (GH) treatment in prepubertal and pubertal children with isolated GH deficiency--model validation in an observational setting (GeNeSIS). J Pediatr Endocrinol Metab 20:685–693CrossRefGoogle Scholar
  35. 35.
    Kriström B, Dahlgren J, Niklasson A et al (2009) The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 9:1.  https://doi.org/10.1186/1472-6947-9-1 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ranke M, Lindberg A, Chatelain P et al (1999) Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr 88:122–125.  https://doi.org/10.1111/j.1651-2227.1999.tb14420.x CrossRefGoogle Scholar
  37. 37.
    Allen DB, Backeljauw P, Bidlingmaier M et al (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 174:P1–P9.  https://doi.org/10.1530/EJE-15-0873 CrossRefPubMedGoogle Scholar
  38. 38.
    Noto R, Maneatis T, Frane J et al (2011) Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of the Genentech National Cooperative Growth Study. J Pediatr Endocrinol Metab 24:627–631CrossRefGoogle Scholar
  39. 39.
    Witbreuk M, van Kemenade FJ, van der Sluijs JA et al (2013) Slipped capital femoral epiphysis and its association with endocrine, metabolic and chronic diseases: a systematic review of the literature. J Child Orthop 7:213–223.  https://doi.org/10.1007/s11832-013-0493-8 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Bramnert M, Segerlantz M, Laurila E et al (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 88:1455–1463.  https://doi.org/10.1210/jc.2002-020542 CrossRefPubMedGoogle Scholar
  41. 41.
    Child CJ, Zimmermann AG, Chrousos GP et al (2019) Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab 104:379–389.  https://doi.org/10.1210/jc.2018-01189 CrossRefPubMedGoogle Scholar
  42. 42.
    Bakalov VK, Gutin L, Cheng CM et al (2012) Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun 38:315–321.  https://doi.org/10.1016/j.jaut.2012.01.015 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kim JY, Rosenfeld SR, Keyak JH (2001) Increased prevalence of scoliosis in Turner syndrome. J Pediatr Orthop 21:765–766PubMedGoogle Scholar
  44. 44.
    Day GA, McPhee IB, Batch J, Tomlinson FH (2007) Growth rates and the prevalence and progression of scoliosis in short-statured children on Australian growth hormone treatment programmes. Scoliosis 2:3.  https://doi.org/10.1186/1748-7161-2-3 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Baxter L, Bryant J, Cave CB, Milne R (2007) Recombinant growth hormone for children and adolescents with Turner syndrome. In: Bryant J (ed) Cochrane database of systematic reviews. John Wiley & Sons, Ltd, Chichester, p CD003887Google Scholar
  46. 46.
    Bolar K, Hoffman AR, Maneatis T, Lippe B (2008) Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab 93:344–351.  https://doi.org/10.1210/jc.2007-1723 CrossRefPubMedGoogle Scholar
  47. 47.
    Quigley CA, Child CJ, Zimmermann AG et al (2017) Mortality in children receiving growth hormone treatment for growth disorders: data from the GeNeSIS observational program. J Clin Endocrinol Metab.  https://doi.org/10.1210/jc.2017-00214

Copyright information

© Hellenic Endocrine Society 2019

Authors and Affiliations

  • I. Kosteria
    • 1
  • K. Aloumanis
    • 2
    Email author
  • C. Kanaka-Gantenbein
    • 1
  • E. Vlachopapadopoulou
    • 3
  • S. Michalacos
    • 3
  • L. Stamoyannou
    • 4
  • E. Drossinos
    • 2
  • G. Chrousos
    • 1
  • for the Hellenic GeNeSIS study group
  1. 1.Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Medical SchoolNational and Kapodistrian University of Athens, “Agia Sophia” Children’s HospitalAthensGreece
  2. 2.Department of Medical ResearchPharmaserve-Lilly SACIKifissiaGreece
  3. 3.Department of GrowthP. & A. Kyriakou Children’s HospitalAthensGreece
  4. 4.First Pediatric Clinic, P. & A. Kyriakou Children’s HospitalAthensGreece

Personalised recommendations